Oral rimegepant as a preventive treatment of migraine: a plain language summary of a clinical study
Year: 2025
Type: article
Abstract: Plain Language SummaryWhat is this summary about?This is a summary of an original clinical study that tested the use of rimegepant for the preventive treatment of migraine. The researchers wanted to know if taking rimegepant every other day would help people have fewer migraine days each month.How was the study conducted?People were assigned to receive one of the study medicines, either rimegepant or placebo. The placebo was a tablet that looked just like the rimegepant tablet but did not contain any rimegepant. People took one tablet every other day for 12 weeks regardless of having a migraine attack that day. The goal of treatment was to prevent future migraine attacks. It was measured by counting the number of migraine days per month.What were the results?People who took rimegepant had a greater reduction in migraine days per month than people who took placebo. Migraine days per month with moderate or severe pain were reduced by at least half (more than or equal to 50%) for about half of the people who took rimegepant. The occurrence of side effects was similar in people who took rimegepant or placebo. Each of the most common side effects occurred in less than 5% of people and nearly all were mild or moderate. Rimegepant, taken every other day, is an effective preventive treatment of migraine with few side effects.This is an abstract of the Plain Language Summary of Publication article.View the full Plain Language Summary PDF of this article to read the full-text
Source: Pain Management
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Funder: Pfizer
OpenAlex ID: W4412409090